The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 08, 2019
Filed:
Mar. 21, 2018
Applicant:
Board of Regents, the University of Texas System, Austin, TX (US);
Inventors:
Michael J. McGinity, San Antonio, TX (US);
Feng Zhang, Pflugerville, TX (US);
John R. Floyd, San Antonio, TX (US);
James W. McGinity, Austin, TX (US);
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/36 (2006.01); A61K 47/14 (2017.01); A61K 31/337 (2006.01); A61K 31/538 (2006.01); A61K 31/573 (2006.01); A61K 33/24 (2019.01); A61K 9/00 (2006.01); A61K 31/282 (2006.01); A61K 31/495 (2006.01); A61K 39/395 (2006.01); A61K 31/436 (2006.01); A61K 31/4745 (2006.01); A61K 31/40 (2006.01); A61K 31/704 (2006.01); A61K 31/519 (2006.01); A61K 31/155 (2006.01); A61K 31/198 (2006.01); A61K 31/661 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61L 27/54 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0085 (2013.01); A61K 9/0024 (2013.01); A61K 31/155 (2013.01); A61K 31/198 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/40 (2013.01); A61K 31/436 (2013.01); A61K 31/4745 (2013.01); A61K 31/495 (2013.01); A61K 31/519 (2013.01); A61K 31/538 (2013.01); A61K 31/573 (2013.01); A61K 31/661 (2013.01); A61K 31/704 (2013.01); A61K 33/24 (2013.01); A61K 39/3955 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/36 (2013.01); A61L 27/54 (2013.01); A61L 2430/32 (2013.01);
Abstract
The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain.